PL2647637T3 - Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf - Google Patents

Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf

Info

Publication number
PL2647637T3
PL2647637T3 PL11844745T PL11844745T PL2647637T3 PL 2647637 T3 PL2647637 T3 PL 2647637T3 PL 11844745 T PL11844745 T PL 11844745T PL 11844745 T PL11844745 T PL 11844745T PL 2647637 T3 PL2647637 T3 PL 2647637T3
Authority
PL
Poland
Prior art keywords
purinylpyridinylamino
preparation
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
Prior art date
Application number
PL11844745T
Other languages
English (en)
Inventor
Eun Kyong Shim
Nam Doo Kim
Tae Bo Shim
Seung Yong Kim
Original Assignee
Medpacto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medpacto Inc filed Critical Medpacto Inc
Publication of PL2647637T3 publication Critical patent/PL2647637T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
PL11844745T 2010-12-02 2011-11-25 Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf PL2647637T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20100122047 2010-12-02
KR1020110124360A KR101364658B1 (ko) 2010-12-02 2011-11-25 신규한 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 Ｒａｆ키나제의 저해활성을 가지는 약학적 조성물
PCT/KR2011/009091 WO2012074249A2 (ko) 2010-12-02 2011-11-25 신규한 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 Ｒａｆ키나제의 저해활성을 가지는 약학적 조성물
EP11844745.7A EP2647637B1 (en) 2010-12-02 2011-11-25 Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredient

Publications (1)

Publication Number Publication Date
PL2647637T3 true PL2647637T3 (pl) 2016-06-30

Family

ID=46172371

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11844745T PL2647637T3 (pl) 2010-12-02 2011-11-25 Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf

Country Status (11)

Country Link
US (1) US9216981B2 (pl)
EP (1) EP2647637B1 (pl)
JP (1) JP5689182B2 (pl)
KR (1) KR101364658B1 (pl)
CN (1) CN103339132B (pl)
AU (1) AU2011337461B2 (pl)
CA (1) CA2820550C (pl)
ES (1) ES2562010T3 (pl)
PL (1) PL2647637T3 (pl)
RU (1) RU2550038C2 (pl)
WO (1) WO2012074249A2 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780341B1 (en) * 2011-11-14 2019-02-13 Chia Tai Tianqing Pharmaceutical Group Co.,Ltd Kinase modulating compounds, compositions containing the same and use thereof
CN103102349B (zh) * 2011-11-14 2017-03-15 北京赛林泰医药技术有限公司 蛋白激酶抑制剂及其组合物和用途
CN103387576A (zh) * 2013-08-09 2013-11-13 中国药科大学 基于嘌呤结构的芳酰胺类Raf激酶抑制剂及其制备方法和用途
CN108602824A (zh) * 2016-01-15 2018-09-28 正大天晴药业集团股份有限公司 一种调节激酶化合物的对甲苯磺酸盐及其结晶
SG11201806596TA (en) * 2016-02-03 2018-09-27 Samjin Pharmaceutical Co Ltd Pyridine derivative inhibiting raf kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof
CA2969295A1 (en) * 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
CA2564355C (en) * 2004-05-07 2012-07-03 Amgen Inc. Protein kinase modulators and method of use
US20080188483A1 (en) * 2005-03-15 2008-08-07 Irm Llc Compounds and Compositions as Protein Kinase Inhibitors
KR20080092412A (ko) 2006-02-06 2008-10-15 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
US8557830B2 (en) * 2007-06-07 2013-10-15 Amgen Inc. RAF kinase modulators and methods of use
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
EP2780341B1 (en) 2011-11-14 2019-02-13 Chia Tai Tianqing Pharmaceutical Group Co.,Ltd Kinase modulating compounds, compositions containing the same and use thereof

Also Published As

Publication number Publication date
US9216981B2 (en) 2015-12-22
WO2012074249A2 (ko) 2012-06-07
CA2820550C (en) 2016-02-23
EP2647637A2 (en) 2013-10-09
KR101364658B1 (ko) 2014-02-19
JP2013545768A (ja) 2013-12-26
CN103339132B (zh) 2017-02-15
CN103339132A (zh) 2013-10-02
EP2647637B1 (en) 2016-02-03
KR20120060744A (ko) 2012-06-12
AU2011337461A1 (en) 2013-07-11
RU2013129993A (ru) 2015-01-10
ES2562010T3 (es) 2016-03-02
EP2647637A4 (en) 2013-11-20
AU2011337461B2 (en) 2015-04-02
RU2550038C2 (ru) 2015-05-10
US20130317023A1 (en) 2013-11-28
JP5689182B2 (ja) 2015-03-25
CA2820550A1 (en) 2012-06-07
WO2012074249A3 (ko) 2012-08-23

Similar Documents

Publication Publication Date Title
WO2011093672A3 (en) Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase
EP2522653A4 (en) BIGUANIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE SUBSTANCE
HK1199725A1 (en) Heterocyclic compounds and uses thereof
HK1198443A1 (en) Heterocyclic compounds and uses thereof
LT2808325T (lt) Pakeistieji azolai, antivirusinis aktyvus ingredientas, farmacinė kompozicija, jų gavimo ir panaudojimo būdas
HK1207069A1 (en) Heterocyclic compounds and uses thereof
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
ZA201304858B (en) Active ingredient combinations comprising pyridylethylbenzamides and other active ingredients
ZA201405673B (en) Arylalkyloxy pyrimidine derivative, pesticide for agricultural and horticultural use containing arylalkyloxy pyrimidine derivative as active ingredient, and use of same
IL231226A (en) Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases
WO2012064973A3 (en) Heterocyclic compounds and uses thereof
ZA201707096B (en) Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient
PL2647637T3 (pl) Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf
KR20180085049A (ko) 아리피프라졸을 유효 성분으로 포함하는 케이크 형상 조성물이 함유된 의료용 기구 및 아리피프라졸을 유효 성분으로 포함하는 케이크 형상 조성물
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
IL231050A0 (en) Pyridines are converted in 4,5,6,7 tetrahydro-1hydrogen-pyrazolo[3,4-si], their use as medicine and medical preparations containing them
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2011005052A8 (en) Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same
IL225105A (en) Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs
PT2722322T (pt) Derivado de 1,3-di-oxo-indeno, seu sal farmaceuticamente aceitável ou isómero ótico, seu método de preparação, e composição farmacêutica contendo o mesmo como ingrediente ativo, antiviral
EP2476420B8 (en) Pharmaceutical composition having antimicrobial and fast-healing activity for external administration, process for preparing same
SI3882244T1 (sl) Spojina, farmacevtsko sprejemljiva sol ali optični izomer le-te, postopek za njeno pripravo in farmacevtski sestavek za preprečevanje ali zdravljenje virusnih bolezni, ki jo vsebuje kot učinkovino
WO2013072770A3 (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
SI3611158T1 (sl) Derivat 1,3-di-okso-indena, farmacevtsko sprejemljiva sol ali optični izomer le-tega, postopek priprave le-tega in farmacevtski sestavek, ki ga vsebuje kot protivirusno učinkovino
ZA201803722B (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof